Communiqués Photocure ASA

Actions

PHO

NO0010000045

Produits pharmaceutiques

Marché Fermé - Oslo Bors Autres places de cotation 16:45:00 30/06/2026			Varia. 5j.	Varia. 1 janv.
59,30 ^NOK	-1,33%		-1,98%	-16,95%

30/06	Photocure : départ à la retraite du directeur financier	MT
16/06	DNB Carnegie reprend le suivi de Photocure avec une recommandation à l'achat et un objectif de cours de 82 couronnes norvégiennes	FW

Communiqués

30/06	Photocure ASA - CFO transition	AQ
26/06	Photocure ASA: Annual general meeting held	AQ
08/06	Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer	AQ
05/06	Photocure ASA - Notice of the Annual General Meeting 26 June 2026	AQ
04/06	Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics	AQ
18/05	AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study	AQ
07/05	Photocure ASA: Results for the first quarter of 2026	AQ
04/05	New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer	AQ
30/04	Photocure ASA: Invitation to presentation of first quarter 2026 financial results	AQ
27/04	Photocure ASA: Annual Report 2025	AQ
20/04	Photocure ASA: Update on milestone payments from Asieris Pharmaceuticals	AQ
17/04	Photocure : Asieris publishes Annual Report and shares Market approval of Richard Wolf System blue equipment in China	PU
13/04	Financial calendar	AQ
13/04	Photocure ASA: Update on Regulatory Classification for OAY Equipment	AQ
07/04	Photocure : Blue Light Cystoscopy demonstrates cost neutrality through reduced recurrence in real-world BRAVO study	PU
28/03	Photocure : Update on KARL STORZ’s Citizen Petition	PU
16/03	Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway	AQ
03/03	Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions	AQ
27/02	Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe	AQ
18/02	Photocure ASA: Results for the fourth quarter of 2025	AQ
11/02	Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results	AQ
12/01	New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment	AQ
08/01	New publication: examining 12-months recurrence-free survival following photo coagulation of bladder tumor versus TUR-BT	PU
08/12	The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison	AQ
19/11	New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management	AQ